Prosecution Insights
Last updated: November 04, 2026
Application No. 18/694,266

CRYSTALLINE FORM OF ANSERINE, AND METHOD OF PRODUCING THE CRYSTALLINE FORM OF ANSERINE

Non-Final OA §102§112
Filed
Mar 21, 2024
Priority
Sep 24, 2021 — JP 2021-155549 +1 more
Examiner
CHEN, PO-CHIH
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tokai Bussan Co. Ltd.
OA Round
1 (Non-Final)
74%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
89%
With Interview

Examiner Intelligence

Grants 74% — above average
74%
Career Allowance Rate
576 granted / 775 resolved
+14.3% vs TC avg
Moderate +15% lift
Without
With
+14.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
57 currently pending
Career history
829
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
33.2%
-6.8% vs TC avg
§102
19.0%
-21.0% vs TC avg
§112
30.8%
-9.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 775 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAIL ACTION This office action is a response to a 371 application filed -----3/21/2024, which is a national stage application of PCT/JP2022/035342 filed 9/22/2022, which claims foreign priority to JP2021-155549 filed 9/24/2021. As filed, claims 1-12 are pending. Election/Restrictions Applicant’s election of in the reply filed on Group I – Claims 1-4 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claims 5-12 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Information Disclosure Statement The information disclosure statement (IDS) submitted on 3/21/2024 and 6/2/2024 has been considered by the Examiner. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 3 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 3, the claim is dependent of claim 1, and claim 3 recites the phrase, “the purity of carnosine”, wherein the word, “the”, requires antecedent basis, and it is unclear where applicant has defined “a” purity of carnosine in claim 1 or 3. Without antecedent basis, the claim is rendered indefinite. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 2 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by Foreign Patent Application Publication No. JP2005-82571, hereinafter Hiraoka. See IDS filed 3/21/2024. Regarding claim 2, Hiraoka, for instance, teaches a crystal of L-anserine having a melting point of 238-241oC, which meets all the limitations of this claim. PNG media_image1.png 470 736 media_image1.png Greyscale (paragraph 0041) PNG media_image2.png 126 722 media_image2.png Greyscale (paragraph 0043) Claim Objections Claim 3 is objected to because of the following informalities: Regarding claim 3, the claim recites the phrase, “the purity of anserine”. Such expressions can be clarified by reciting -- –. Appropriate correction is required. Allowable Subject Matter Claims 1 and 4 are allowed. Conclusion Claims 2 and 3 are rejected. Claims 1 and 4 are allowed. Claim 3 is objected. Claims 5-12 are withdrawn. Telephone Inquiry Any inquiry concerning this communication or earlier communications from the examiner should be directed to PO-CHIH CHEN whose telephone number is (571)270-7243. The examiner can normally be reached Monday - Friday 10:00 am to 6:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks can be reached at (571)270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PO-CHIH CHEN/Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Mar 21, 2024
Application Filed
Oct 30, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780809
8-(PICOLINAMIDE) SUBSTITUTED COUMARIN COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12729209
MACROCYCLIC COMPOUNDS AND METHODS OF TREATMENT
3y 5m to grant Granted Sep 08, 2026
Patent 12715852
PREPARATION OF OPTICALLY ACTIVE ENANTIOMERS OF PIPERONYL AMINES BY RESOLUTION OF THE DIASTEREOMERIC SALTS
3y 11m to grant Granted Aug 25, 2026
Patent 12714693
USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS
1y 8m to grant Granted Aug 25, 2026
Patent 12703676
SYSTEMS AND METHODS FOR PRODUCING NITRILES
2y 2m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
74%
Grant Probability
89%
With Interview (+14.7%)
2y 5m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 775 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month